

Shareholders approve key resolutions at the 2026 Annual General Shareholders' Meeting

- *In 2025, the company reported revenue of €7,524 million, a 7% increase, and more than doubled its net profit to €402 million*
- *Shareholders approved measures aimed at enhancing the company's financial flexibility, including the renewal of authorizations related to share capital and share repurchases*

Barcelona, Spain, June 18, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, announced that its shareholders approved the main resolutions submitted for vote at the 2026 Annual General Shareholders' Meeting, held today at the company's headquarters in Sant Cugat del Vallès, Barcelona.

Shareholders endorsed the key proposals presented by the Board of Directors, including approval of the parent company and consolidated annual financial statements, the non-financial and sustainability reporting statement, and the Board's management of the company during the fiscal year.

Shareholders also approved:

- The re-election of Montserrat Muñoz Abellana and Susana González Rodríguez as members of the Board of Directors;
- the reappointment of Deloitte Auditores, S.L. as the independent auditor of the Company and its consolidated group for fiscal years 2027, 2028, and 2029;
- amendments to the Company's Directors' Remuneration Policy;
- the Annual Directors' Remuneration Report, on an advisory basis; and
- a reduction of the Company's share capital, up to a maximum amount representing 10% of the share capital as of the date of the resolution, through the cancellation of treasury Class A and Class B shares.

Shareholders also expressed support for Grifols' strategy to further strengthen its financial position, drive profitable business growth, and continue advancing its operational and innovation priorities.

A total of 579 shareholders attended or were represented at the Annual General Shareholders' Meeting for fiscal year 2025, representing 261,093,456 shares and 61.27% of the Company's voting share capital.

During the meeting, Grifols presented its 2025 financial results. The company reported revenue of €7,524 million, up 7% year-over-year, and more than doubled net profit to €402 million. Adjusted EBITDA reached €1,825 million, while free cash flow totaled €468 million, driven by EBITDA growth, working capital management, normalized capital expenditures, and lower financing costs.

Anne-Catherine Berner, Non-Executive Chairwoman of Grifols, highlighted the importance of maintaining a long-term perspective in the company's development: "We are evaluating opportunities to unlock the value of Grifols' exceptional assets and enhance our financial flexibility, while preserving the company's long-term strength and growth potential".

Raimon Grifols, Vice Chairman of the Board of Directors, emphasized shareholders' confidence in the company's future: "For more than a century, Grifols has grown guided by a long-term vision, a strong commitment to innovation, and a clear dedication to serving patients. Today, we continue to move forward to strengthen the company and contribute to a more resilient, balanced, and sustainable global plasma supply model that addresses the growing needs of patients and healthcare systems worldwide. On behalf of the Board of Directors, I would like to thank our shareholders for their continued trust in Grifols. Their support motivates us to keep preparing the company to lead the future of an industry that is essential to global health."

Commitment to Sustainability and Corporate Governance

The Annual General Shareholders' Meeting also endorsed Grifols' performance in sustainability and corporate governance through approval of the Company's 2025 Non-Financial Information and Sustainability Statement.

Grifols remains committed to responsible and transparent management aligned with the highest international standards of corporate governance, business ethics, and sustainability, while continuing to advance the goals set forth in its Grifols Agenda 2030.

For more information: Grifols 2026 Annual General Shareholders' Meeting and 2025 Integrated Annual and Sustainability Report.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Phone: +34 93 571 00 02

INVESTORS:

Investor Relations & Sustainability

investors@grifols.com – inversores@grifols.com

sustainability@grifols.com – sostenibilidad@grifols.com

Phone: +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.